# The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Participants Who Have Already Been Treated With ALN-TTR02 (Patisiran)

> **NCT02510261** · PHASE3 · COMPLETED · sponsor: **Alnylam Pharmaceuticals** · enrollment: 211 (actual)

## Conditions studied

- Amyloidosis

## Interventions

- **DRUG:** Patisiran

## Key facts

- **NCT ID:** NCT02510261
- **Lead sponsor:** Alnylam Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07-16
- **Primary completion:** 2022-11-23
- **Final completion:** 2022-11-23
- **Target enrollment:** 211 (ACTUAL)
- **Last updated:** 2023-12-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02510261

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02510261, "The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Participants Who Have Already Been Treated With ALN-TTR02 (Patisiran)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02510261. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*